Cantor Fitzgerald analyst Li Watsek downgraded Affimed Therapeutics (NASDAQ: AFMD) from Overweight to Neutral.The analyst comments "Affimed disclosed initiation of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE